Physician profile
Bradley Britton
NPI 1033112016
$25,369.49
in general payments reported to CMS, 2019-2025
36 companies · $2,365 in 2025
The $2,365 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,414 · 2021: $3,138 · 2022: $2,552 · 2023: $1,358 · 2024: $3,088 · 2025: $2,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,677 · Travel and Lodging: $1,109 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,676.61 |
| Travel and Lodging | $1,109.09 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $8,598.87 | 2019-2022 | |
| Alcon Vision LLC | $3,642.90 | 2019-2025 | Clareon Panoptix Pro, Clareon, Simbrinza |
| Bausch & Lomb Americas INC. | $2,301.22 | 2022-2025 | Stellaris Elite, Teneo, Envista Aspire Iol |
| Carl Zeiss Meditec USA, INC. | $1,288.58 | 2021-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,267.82 | 2019-2021 | |
| Glaukos Corporation | $834.00 | 2019-2024 | Istent Trabecular Micro-Bypass Stent System, Istent Inject Trabecular Micro-Bypass System, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Ocular Therapeutix, INC. | $665.64 | 2021-2025 | Dextenza |
| Carl Zeiss Meditec, INC. | $607.49 | 2019-2020 | |
| Lensar, INC. | $581.56 | 2022-2024 | Lensar Laser System |
| New World Medical,INC. | $526.67 | 2019-2024 | Streamline, Ahmed Glaucoma Valve, Clearpath |
| Aerie Pharmaceuticals, INC. | $472.76 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $462.69 | 2024-2025 | Xdemvy |
| Abbvie INC. | $426.28 | 2022-2024 | Lumigan, Alphagan P, Durysta |
| The Cameron-Ehlen Group, INC. | $374.26 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $369.32 | 2022-2025 | Catalys System, Tecnis Iol, Tecnis Iol |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $336.66 | 2021-2023 | |
| Harrow Eye, LLC | $293.01 | 2024-2025 | Vevye |
| Rxsight INC | $284.84 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Ani Pharmaceuticals, INC. | $275.46 | 2024-2025 | Purified Cortrophin Gel |
| Dompe US, INC. | $216.44 | 2021-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $201.10 | 2023-2024 | Acthar |
| Sight Sciences, INC. | $190.49 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $173.75 | 2019-2025 | |
| Shire North American Group INC | $139.61 | 2019 | |
| Eyevance Pharmaceuticals LLC | $137.22 | 2021-2022 | |
| Ivantis, INC | $136.52 | 2019 | |
| Optos, INC. | $108.14 | 2022 | |
| Ellexiscience | $104.50 | 2019 | |
| Staar Surgical Company | $96.43 | 2019 | |
| Omeros Corporation | $94.22 | 2019 | |
| Apellis Pharmaceuticals, INC. | $53.57 | 2025 | Syfovre |
| Oyster Point Pharma, INC. | $29.68 | 2022 | |
| Eyepoint US, INC. | $29.22 | 2021 | |
| Mallinckrodt Enterprises LLC | $23.49 | 2019 | |
| Rayner Intraocular Lenses Limited | $13.10 | 2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Kala Pharmaceuticals, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Britton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.